6533b7d0fe1ef96bd125af2b
RESEARCH PRODUCT
Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper
Stefania GoriNicola SilvestrisMonica MontagnaniAntonella ArgentieroGiordano D. BerettaMarco GalloStella D'oronzoPaolo Di BartoloSilvia AcquatiPietro FerrariAntonio RussoRomano Danesisubject
diabetes; dyslipidemia; hypercholesterolemia; hyperglycemia; hypertriglyceridemia; immunotherapy; metabolic effect; targeted therapy; Consensus; Humans; Immunologic Factors; Italy; Medical Oncology; Neoplasms; Physicians0301 basic medicinemedicine.medical_specialtyConsensusSettore MED/06 - Oncologia MedicaImmune checkpoint inhibitorsmedicine.medical_treatmentPatient riskhypertriglyceridemiaMedical OncologyTargeted therapy03 medical and health sciences0302 clinical medicineMultidisciplinary approachNeoplasmsPhysiciansmedicineHumansImmunologic FactorsIntensive care medicineAdverse effectdiabeteshypercholesterolemiabusiness.industrydyslipidemiametabolic effectHematologytargeted therapy030104 developmental biologyOncologyItalyClinical evidence030220 oncology & carcinogenesisMetabolic effectsPosition paperhyperglycemiaimmunotherapybusinessdescription
The growing insights in the next-generation immunotherapy and the state-of-the-art advancement in targeted-agents significantly improved clinical outcome of cancer patients by pointing towards a unexplored Achilles' heel. Novel toxicity profiles have been uncovered, representing unmet medical needs. Thus, a panel of expert provide comprehensive pharmacological and clinical evidence, to provide a patient-tailored approach to metabolic adverse events associated with novel anti-cancer treatments. Prompted by the need of a multidisciplinary cooperation, a working group of Associazione Italiana Oncologia Medica (AIOM), Associazione Medici Diabetologi (AMD) and Societa Italiana Farmacologia (SIF) examined the available literature data. The identification of patient risk profile and the characterization of metabolic effects of novel anti-tumour drugs is clearly a clinical challenge that can be addressed by a multidisciplinary clinical approach. Therefore, this review pinpoints the relevance of the challenging profiling of the patient suffering from dysmetabolic conditions induced by the novel therapeutics in medical oncology.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-01-01 |